Thus, these findings also illustrate the essential role of FGF-2 in regulating CSCs via the Mek/Erk signaling pathway, thereby suggesting that inhibition of FGFR and/or Mek signaling represents a potential novel therapeutic option for targeting CSCs in ESCC [179]. Here, MAP2K7 is linked to esophageal squamous cell carcinoma.